IP Library Granted Patent US 9,702,883
Granted Patent B2
US 9,702,883 · App. 14/885,443 · Granted Jul 11, 2017

Peptides, devices, and methods for the detection of anaplasma antibodies

Inventors: Rajesh K. Mehra (Hayward, CA); Kenneth P. Aron (San Francisco, CA); Dennis M. Bleile (San Ramon, CA); Andrew P. Rogers (Union City, CA); Timothy P. Forsyth (Hayward, CA); Jeremy D. Walker (Castro Valley, CA); Christina R. Cuesico (Fremont, CA)
Assignee: ABAXIS, INC.
G01N33/6854C07K14/195G01N33/56911G01N2333/29G01N2469/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,702,883
App. No.
14/885,443
Granted
Jul 11, 2017
Kind
B2
Abstract

The invention provides populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the Anaplasma Outer Membrane Protein proteins. The invention also provides devices, methods, and kits comprising the populations of isolated peptides useful for the detection of antibodies that bind to Anaplasma antigens and the diagnosis of anaplasmosis. Methods of identifying the particular Anaplasma species infecting a subject using the peptide populations of the invention are also disclosed.

Claims (37)

1. A method for detecting in a sample an antibody to an epitope of an Anaplasma antigen, the method comprising:

(i) contacting a sample with a composition comprising a population of isolated peptides, said population comprising three or more different peptides, wherein each peptide in the population comprises a sequence selected from:

(a) SEQ ID NO: 1, wherein X 9 is an amino acid selected from the group consisting of I, P and H, X 17 is an amino acid selected from the group consisting of I, W, and Y, X 21 is an amino acid selected from the group consisting of R, D, and N, X 28 is an amino acid selected from the group consisting of E and N, and X 31 is an amino acid selected from the group consisting of L and V;

(b) SEQ ID NO: 2, wherein X 3 is an amino acid selected from the group consisting of L, V and A, X 7 is an amino acid selected from the group consisting of K, N and Q, X 11 is an amino acid selected from the group consisting of R, D, and N, and X 15 is an amino acid selected from the group consisting of E, N and Q;

(c) SEQ ID NO: 3, wherein X 5 is an amino acid selected from the group consisting of V and A, X 7 is an amino acid selected from the group consisting of G, I and H, X 11 is an amino acid selected from the group consisting of E, N, and Q, X 18 is an amino acid selected from the group consisting of D and N, X 21 is an amino acid selected from the group consisting of R, D, and N, X 25 is an amino acid selected from the group consisting of Q, D, and E, X 28 is an amino acid selected from the group consisting of and E or N, X 31 is an amino acid selected from the group consisting of L and V, X 45 is an amino acid selected from the group consisting of K and Q, X 48 is an amino acid selected from the group consisting of F and V, X 51 is an amino acid selected from the group consisting of D and N, X 54 is an amino acid selected from the group consisting of E and Q, X 57 is an amino acid selected from the group consisting of S and Q, X 60 is an amino acid selected from the group consisting of F and W, X 63 is an amino acid selected from the group consisting of I and V, and X 66 is an amino acid selected from the group consisting of Q and D;

(d) SEQ ID NO: 4, wherein X 6 is an amino acid selected from the group consisting of K and Q, X 9 is an amino acid selected from the group consisting of F and V, X 12 is an amino acid selected from the group consisting of D and N, X 15 is an amino acid selected from the group consisting of E and Q, X 18 is an amino acid selected from the group consisting of S and Q, X 21 is an amino acid selected from the group consisting of F and W, X 24 is an amino acid selected from the group consisting of I and V, and X 27 is an amino acid selected from the group consisting of Q and D;

(e) SEQ ID NO: 5, wherein X 2 is an amino acid selected from the group consisting of I and V, X 10 is an amino acid selected from the group consisting of S and Y, and X 23 is an amino acid selected from the group consisting of E and N;

(f) SEQ ID NO: 6;

(g) SEQ ID NO: 7, wherein X 5 is an amino acid selected from the group consisting of S and Q, X 9 is an amino acid selected from the group consisting of F and Y, X 13 is an amino acid selected from the group consisting of R and H, X 16 is an amino acid selected from the group consisting of W and Y, X 18 is an amino acid selected from the group consisting of S and Q, X 22 is an amino acid selected from the group consisting of K and H, and X 27 is an amino acid selected from the group consisting of N and D;

(h) SEQ ID NO: 8, wherein X 10 is an amino acid selected from the group consisting of V, L and I, and X 11 is an amino acid selected from the group consisting of A and L; and

(i) SEQ ID NO: 9, wherein X 5 is an amino acid selected from the group consisting of V and A, X 7 is an amino acid selected from the group consisting of G, I and H, X 11 is an amino acid selected from the group consisting of E, N, and Q, X 21 is an amino acid selected from the group consisting of R, D, and N, X 25 is an amino acid selected from the group consisting of Q, D, and E, X 28 is an amino acid selected from the group consisting of E and N, and X 31 is an amino acid selected from the group consisting of L and V; and

(ii) detecting formation of an antibody-peptide complex comprising one or more of the three or more different peptides in the composition, wherein formation of said complex is indicative of an antibody to an epitope of an Anaplasma antigen being present in said sample.

2. The method of claim 1 , wherein said Anaplasma antigen is from Anaplasma phagocytophilum, Anaplasma platys , or Anaplasma marginate.

3. The method of claim 1 , wherein the population of isolated peptides is immobilized to a solid support optionally through a metallic nanolayer.

4. The method of claim 1 , wherein said detecting step comprises (i) performing an ELISA assay, (ii) running a lateral flow assay, (iii) performing an agglutination assay, (iv) performing a Western blot, a slot blot, or dot blot, (v) performing a wavelength shift assay, (vi) performing an Indirect Fluorescent Antibody test , or (vii) running the sample through an analytical or centrifugal rotor.

5. The method of claim 1 , wherein said sample is from a human, canine, or feline subject.

6. The method of claim 1 , wherein said sample is a blood, serum, plasma, cerebrospinal fluid, tissue extract, urine, or saliva sample.

7. The method of claim 1 , wherein one of the three or more different peptides comprises SEQ ID NO: 6.

8. The method of claim 1 , wherein one of the three or more different peptides comprises SEQ ID NO: 3.

9. The method of claim 1 , wherein the three or more different peptides comprise SEQ ID NOs: 3, 6, and 7.

10. A method for diagnosing anaplasmosis in a subject, the method comprising:

(i) contacting a sample from the subject with a composition comprising a population of isolated peptides, said population comprising three or more different peptides, wherein each peptide in the population comprises a sequence selected from:

(a) SEQ ID NO: 1, wherein X 9 is an amino acid selected from the group consisting of I, P and H, X 17 is an amino acid selected from the group consisting of I, W, and Y, X 21 is an amino acid selected from the group consisting of R, D, and N, X 28 is an amino acid selected from the group consisting of E and N, and X 31 is an amino acid selected from the group consisting of L and V;

(b) SEQ ID NO: 2, wherein X 3 is an amino acid selected from the group consisting of L, V and A, X 7 is an amino acid selected from the group consisting of K, N and Q, X 11 is an amino acid selected from the group consisting of R, D, and N, and X 15 is an amino acid selected from the group consisting of E, N and Q;

(c) SEQ ID NO: 3, wherein X 5 is an amino acid selected from the group consisting of V and A, X 7 is an amino acid selected from the group consisting of G, I and H, X 11 is an amino acid selected from the group consisting of E, N, and Q, X 18 is an amino acid selected from the group consisting of D and N, X 21 is an amino acid selected from the group consisting of R, D, and N, X 25 is an amino acid selected from the group consisting of Q, D, and E, X 28 is an amino acid selected from the group consisting of and E or N, X 31 is an amino acid selected from the group consisting of L and V, X 45 is an amino acid selected from the group consisting of K and Q, X 48 is an amino acid selected from the group consisting of F and V, X 51 is an amino acid selected from the group consisting of D and N, X 54 is an amino acid selected from the group consisting of E and Q, X 57 is an amino acid selected from the group consisting of S and Q, X 60 is an amino acid selected from the group consisting of F and W, X 63 is an amino acid selected from the group consisting of I and V, and X 66 is an amino acid selected from the group consisting of Q and D;

(d) SEQ ID NO: 4, wherein X 6 is an amino acid selected from the group consisting of K and Q, X 9 is an amino acid selected from the group consisting of F and V, X 12 is an amino acid selected from the group consisting of D and N, X 15 is an amino acid selected from the group consisting of E and Q, X 18 is an amino acid selected from the group consisting of S and Q, X 21 is an amino acid selected from the group consisting of F and W, X 24 is an amino acid selected from the group consisting of I and V, and X 27 is an amino acid selected from the group consisting of Q and D;

(e) SEQ ID NO: 5, wherein X 2 is an amino acid selected from the group consisting of I and V, X 10 is an amino acid selected from the group consisting of S and Y, and X 23 is an amino acid selected from the group consisting of E and N;

(f) SEQ ID NO: 6;

(g) SEQ ID NO: 7, wherein X 5 is an amino acid selected from the group consisting of S and Q, X 9 is an amino acid selected from the group consisting of F and Y, X 13 is an amino acid selected from the group consisting of R and H, X 16 is an amino acid selected from the group consisting of W and Y, X 18 is an amino acid selected from the group consisting of S and Q, X 22 is amino acid from the group consisting of K and H, and X 27 is an amino acid selected from the group consisting of N and D;

(h) SEQ ID NO: 8, wherein X 10 is an amino acid selected from the group consisting of V, L and I, and X 11 is an amino acid selected from the group consisting of A and L; and

(i) SEQ ID NO: 9, wherein X 5 is an amino acid selected from the group consisting of V and A, X 7 is an amino acid selected from the group consisting of G, I and H, X 11 is an amino acid selected from the group consisting of E, N, and Q, X 21 is an amino acid selected from the group consisting of R, D, and N, X 25 is an amino acid selected from the group consisting of Q, D, and E, X 28 is an amino acid selected from the group consisting of E and N, and X 31 is an amino acid selected from the group consisting of L and V; and

(ii) detecting formation of an antibody-peptide complex comprising one or more of the three or more different peptides in the composition,

wherein formation of the complex is indicative of the subject having anaplasmosis.

11. The method of claim 10 , wherein said subject is a human, canine, or feline.

12. The method of claim 10 , wherein one of the three or more different peptides comprises SEQ ID NO: 6.

13. The method of claim 10 , wherein one of the three or more different peptides comprises SEQ ID NO: 3.

14. The method of claim 10 , wherein the three or more different peptides comprise SEQ ID NOs: 3, 6, and 7.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2021
From: ABAXIS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 055474/0599 →
CHANGE OF NAME Recorded Mar 3, 2021
From: ABAXIS, INC.
To: ABAXIS LLC
Reel/Frame 055474/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: MEHRA, RAJESH K.; BLEILE, DENNIS M.; ARON, KENNETH P.; FORSYTH, TIMOTHY P.; WALKER, JEREMY D.; ROGERS, ANDREW P.; CUESICO, CRISTINA R.
To: ABAXIS, INC.
Reel/Frame 041754/0247 →
Continuity (3)
Division 14511916 · Oct 10, 2014
Provisional Application 61929655 · Jan 21, 2014
Related Publication 20160109457A1 · Apr 21, 2016